<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/28826/embraca-trial-in-her2-metastatic-breast-cancer?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

EMBRACA Trial in HER2 Metastatic Breast Cancer

Name: EMBRACA Trial in HER2 Metastatic Breast Cancer
Uploaded: 2019-06-26T07:57:58
Duration: 1 min 11 s
Description: Neelima Denduluri MD, Associate Professor, US Oncology Research, Virginia Cancer Specialists shares the results of the phase III EMBARCA trial that compares the efficacy and safety of talazoparib (TALA) to PCT (capecitabine, eribulin, gemcitabine, vinorelbine) in HER2-metastatic breast cancer patients.

00:01:11

Don

3 years 196 Views

Share Add to Report 0 0

Embed (Iframe):

<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/28826/embraca-trial-in-her2-metastatic-breast-cancer?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

Embed (Object):

<div class="embed-responsive embed-responsive-16by9"><object width="640" height="360"><param name="movie" value="https://oncologytube.com/videoEmbed/28826/embraca-trial-in-her2-metastatic-breast-cancer?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit="></param><param name="allowFullScreen" value="true"></param><param name="allowscriptaccess" value="always"></param><embed src="https://oncologytube.com/videoEmbed/28826/embraca-trial-in-her2-metastatic-breast-cancer?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" allowscriptaccess="always" allowfullscreen="true" width="640" height="360"></embed></object></div>

Link (HTML):

<a href="https://oncologytube.com/v/28826?channelName=obr"><img src="https://oncologytubecom.cdn.ypt.me/videos/video_190626195758_0fb0/video_190626195758_0fb0.jpg?cache=15669161571678829655">EMBRACA Trial in HER2 Metastatic Breast Cancer</a>

Link (BBCode):

[url=https://oncologytube.com/v/28826?channelName=obr][img]https://oncologytubecom.cdn.ypt.me/videos/video_190626195758_0fb0/video_190626195758_0fb0.jpg?cache=15669161571678829655[/img]EMBRACA Trial in HER2 Metastatic Breast Cancer[/url]

Sign in now!

Permanent Link

URL Friendly (SEO)

Current Time (SEO)

Category:

Breast

Description:

Neelima Denduluri MD, Associate Professor, US Oncology Research, Virginia Cancer Specialists shares the results of the phase III EMBARCA trial that compares the efficacy and safety of talazoparib (TALA) to PCT (capecitabine, eribulin, gemcitabine, vinorelbine) in HER2-metastatic breast cancer patients.